Insights Into Vepdegestrant (ARV-471): The First-in-Class Estrogen Receptor Proteolysis-Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer

待确认 10 由刘12345 发布于 2026/8/10 17:47:23

DOI:10.1002/cmdc.202501111
作者：Chao Tang, Bin Tian, Bingxing Zhang, Yunfei Zhang, Changhua Ke, Mengxin Chen, Meiyan Wei, Wen Wang, Xintao Deng, Qiannan Zhang, Mengzhou Wang, Ju
文献类型：期刊论文
补充材料：只需要正文

Wiley

Abstract：Vepdegestrant (ARV-471) is an orally bioavailable, proteolysis-targeting chimera (PROTAC)-based estrogen receptor (ER) degrader and is among the most clinically advanced ER-targeting PROTAC

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

12小时前

不是朋友交不起

2fa1363894a111f1941134735aa3bc31.pdf

12小时前

Book学术机器人

2026/8/10 17:47:23 未找到该文献，机器人已退出，请等待人工下载

2026/8/10 17:47:23 Book学术AI机器人收到请求，开始寻找文献

2026/8/10 17:47:23 已向机器人发送请求

12小时前

刘12345 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Physical Society (APS)Four Regimes of Primary Radiation Damage in Tungsten